Keywords
continuous glucose monitoring
type 1 diabetes
hypoglycemia
diabetes technology
How to Cite
Abstract
Background: Intensive insulin therapy by continuous subcutaneous infusion with real-time continuous glucose monitoring is a good treatment option for patients with type 1 diabetes mellitus. The introduction of the advanced closed-loop hybrid system represents a new era in the treatment of type 1 diabetes.
Purpose: To report one of the first successful training sessions with the new Minimed 780G system in a patient with poor metabolic control who had previously used technology.
Case presentation: We present the case of a 59-year-old patient with type 1 diabetes, treated with Mini MedÔ 640G, with a history of poor metabolic control and frequent hypoglycemia, who changed to the Mini MedÔ 780G system. The patient's history records were collected from the training carried out in the endocrinology service of the San Ignacio University Hospital in Bogotá, through the Medtronic CareLinkÔ software, and from the usual follow-ups in the outpatient clinic. At the end of training with the new technology, the patient's time in range improved markedly, without presenting severe hypoglycemia or hyperglycemia.
Discussion and conclusion: The Mini MedÔ 780G system in people with type 1 diabetes, who have not achieved adequate metabolic control with previous technologies, can be an effective and safe tool to improve glycemic control.
References
American Diabetes Association. 6. Glycemic Targets: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(supl. 1):S83-96. https://doi.org/10.2337/dc22-S006
Monnier L, Colette C, Owens DR. The application of simple metrics in the assessment of glycaemic variability. Diabetes Metab. 2018;44(4):313-9. https://doi.org/10.1016/j.diabet.2018.02.008
Horowitz ME, Kaye WA, Pepper GM, Reynolds KE, Patel SR, Knudson KC, et al. An analysis of Medtronic MiniMed 670G insulin pump use in clinical practice and the impact on glycemic control, quality of life, and compliance. Diabetes Res Clin Pract. 2021 jul.;177:108876. https://doi.org/10.1016/j.diabres.2021.108876
Gómez AM, Imitola A, Henao D, García-Jaramillo M, Giménez M, Viñals C, et al. Factors associated with clinically significant hypoglycemia in patients with type 1 diabetes using sensor-augmented pump therapy with predictive low-glucose management: A multicentric study on iberoamerica. Diabetes Metab Syndr. 2021;15(1):267-72. https://doi.org/10.1016/j.dsx.2021.01.002
Choudhary P, Olsen BS, Conget I, Welsh JB, Vorrink L, Shin JJ. Hypoglycemia Prevention and User Acceptance of an Insulin Pump System with Predictive Low Glucose Management. Diabetes Technol Ther. 2016;18(5):288-91. https://doi.org/10.1089/dia.2015.0324
McVean J, Miller J. MiniMedTM780G Insulin pump system with smartphone connectivity for the treatment of type 1 diabetes: overview of its safety and efficacy. Expert Rev Med Devices. 2021;18(6):499-504. https://doi.org/10.1080/17434440.2021.1926984
Medtronic. Getting to know the MINIMED 780g system. 2020. https://www.manualslib.com/download/1963457/Medtronic-Minimed-780g.html
Go?mez AM, Henao D, Parra D, Kerguelen A, Vergara M, Muñoz OM, et al. Virtual training on the hybrid close loop system in people with type 1 diabetes (T1D) during the COVID-19 pandemic. DiabetesMetab Syndr. 2021;15(1):243-7. https://doi.org/10.1016/j.dsx.2020.12.041
Battelino T, Danne T, Bergenstal RM, Amiel S, Beck R, Biester T, et al. Clinical targets for continuous glucose monitoring data interpretation: Recommendations from the international consensus on time in range. Diabetes Care. 2019;42(8):1593-603. https://doi.org/10.2337/dci19-0028
Bergenstal RM, Nimri R, Beck RW, Criego A, Laffel L, Schatz D, et al. A Comparison of Two Hybrid Closed-Loop Systems in Adolescents and Young Adults with Type 1 Diabetes (FLAIR): A Multicentre, Randomised, Crossover Trial. Lancet 2021;397(10270):208-19. https://doi.org/10.1016/S0140-6736(20)32514-9
da Silva J, Lepore G, Battelino T, Arrieta A, Castañeda J, Grossman B, et al. Real-world Performance of the MiniMedTM 780G System: First Report of Outcomes from 4’120 Users. Diabetes Technol Ther. 2022;24(2):113-9. https://doi.org/10.1089/dia.2021.0203
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Revista Colombiana de Endocrinología, Diabetes & Metabolismo